HLS Therapeutics Inc T.HLS

Alternate Symbol(s): HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.

TSX:HLS - Post by User

HLS Therapeutics Inc

Bullboard Posts

Comment by fairweather1on Sep 29, 2013 9:21am

140 Views

Post# 21776209

RE:RE:RE:RE:RE:Forecast NAV at June 30 2014

I don't have time to do your math right now, but I'm wondering if you noted that on the most recently balance sheet, "receivables..." exceeded "payables..." by about 7 million. I take this to mean addtional future cash since a customer like Ford will pay up for sure, though it is not yet recognized as such on the books.

Would this not be over and above the anticipated "regular cash flows" you are hypothesizing. Maybe I've got this wrong. Please clarify if so.

Bullboard Posts

Gold, growth and sustainability in focus for Mandalay Resources